Active	Status	Sponsor type	Region	Phase	Filter
5 Active 12 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
INOpulse (nitric oxide) / Bellerophon Therap
NCT02652429: Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH	Active, not recruiting	3	22	Canada, US	Inhaled Nitric Oxide, iNO	Bellerophon Pulse Technologies	Pulmonary Arterial Hypertension	04/23	12/23
REBUILD, NCT03267108: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension	Terminated	3	145	Canada, US	INOpulse®, Placebo, Open Label Extension	Bellerophon Pulse Technologies	Pulmonary Fibrosis, Pulmonary Hypertension	06/23	06/23
NCT05747508: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis	Active, not recruiting	2	85	US	INOpulse®, Placebo, Long Term Follow Up	Bellerophon	Pulmonary Fibrosis, Pulmonary Hypertension	11/19	12/23
PULSE-EAP-002, NCT05356052: Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis	Available	N/A		NA	INOpulse	Bellerophon	Pulmonary Fibrosis, Pulmonary Hypertension
NCT04358588: Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19	No Longer Available	N/A		NA	iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System	Bellerophon	Coronavirus Infection, COVID-19, Pneumonia, Viral

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
INOpulse (nitric oxide) / Bellerophon Therap
NCT02652429: Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH	Active, not recruiting	3	22	Canada, US	Inhaled Nitric Oxide, iNO	Bellerophon Pulse Technologies	Pulmonary Arterial Hypertension	04/23	12/23
REBUILD, NCT03267108: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension	Terminated	3	145	Canada, US	INOpulse®, Placebo, Open Label Extension	Bellerophon Pulse Technologies	Pulmonary Fibrosis, Pulmonary Hypertension	06/23	06/23
NCT05747508: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis	Active, not recruiting	2	85	US	INOpulse®, Placebo, Long Term Follow Up	Bellerophon	Pulmonary Fibrosis, Pulmonary Hypertension	11/19	12/23
PULSE-EAP-002, NCT05356052: Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis	Available	N/A		NA	INOpulse	Bellerophon	Pulmonary Fibrosis, Pulmonary Hypertension
NCT04358588: Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19	No Longer Available	N/A		NA	iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System	Bellerophon	Coronavirus Infection, COVID-19, Pneumonia, Viral